A Focused Strategy Against Pertussis Toxin

Pertussis toxin is a central virulence factor of Bordetella pertussis and is closely associated with the severe clinical manifestations of whooping cough. The scientific rationale for BioNet’s pertussis-only vaccine is based on inducing immune responses directed against this key component of disease pathogenesis.

During the regulatory evaluation, data demonstrated that the pertussis-only vaccine elicits functional immune responses targeting pertussis toxin. By focusing on antigens that play a direct role in disease severity, the vaccine is designed to provide targeted protection against clinically relevant aspects of pertussis infection.

This antigen-focused approach reflects advances in the understanding of pertussis immunology and the role of toxin neutralisation in protection. The strategy aims to support effective booster immunisation while maintaining a well-characterised safety profile consistent with acellular pertussis vaccines.

Read the full news: VacPertagen Receives EU Approval